RANKL Inhibition Improves Bone Properties in a Mouse Model of Osteogenesis Imperfecta

REFERENCES

• Rauch, F., and Glorieux, F.H. (2004). Osteogenesis imperfecta. Lancet, 363:1377–1385.
   PubMed Web of Science ®Google Scholar
• Gatti, D., Antoniazzi, F., Prizzi, R., (2005). Intravenous neridronate in children with osteogenesis imperfecta: a randomized controlled study. J. Bone. Miner. Res. 20:758–763.
   PubMed Web of Science ®Google Scholar
• Glorieux, F.H., Bishop, N.J., Plotkin, H., (1998). Cyclic administration of pamidronate in children with severe osteogenesis imperfecta. N. Engl. J. Med., 339:947–952.
   PubMed Web of Science ®Google Scholar
• Letocha, A.D., Cintas, H.L., Troendle, J.F., (2005). Controlled trial of pamidronate in children with types III and IV osteogenesis imperfecta confirms vertebral gains but not short-term functional improvement. J. Bone Miner. Res., 20:977–986.
   PubMed Web of Science ®Google Scholar
• Madenci, E., Yilmaz, K., Yilmaz, M., (2006). Alendronate treatment in osteogenesis imperfecta. J. Clin. Rheumatol., 12:53–56.
   PubMed Web of Science ®Google Scholar
• Sakkers, R., Kok, D., and Engelbert, R., (2004). Skeletal effects and functional outcome with olpadronate in children with osteogenesis imperfecta: a 2-year randomised placebo-controlled study. Lancet, 363:1427–1431.
   PubMed Web of Science ®Google Scholar
• Glorieux, F.H. (2007). Experience with bisphosphonates in osteogenesis imperfecta. Pediatrics, 119(suppl 2):S163–S165.
   PubMedGoogle Scholar
• Vallo, A., Rodriguez-Leyva, F., and Rodriguez Soriano, J. (2006). Osteogenesis imperfecta: anthropometric, skeletal and mineral metabolic effects of long-term intravenous pamidronate therapy. Acta Paediatr., 95:332–339.
   PubMed Web of Science ®Google Scholar
• Munns, C.F., Rauch, F., Mier, R.J., (2004). Respiratory distress with pamidronate treatment in infants with severe osteogenesis imperfecta. Bone, 35:231–234.
   PubMed Web of Science ®Google Scholar
• Rauch, F., Munns, C., Land, C., (2006). Pamidronate in children and adolescents with osteogenesis imperfecta: effect of treatment discontinuation. J. Clin. Endocrinol. Metab., 91:1268–1274.
   PubMed Web of Science ®Google Scholar
• Land, C., Rauch, F., and Glorieux, F.H. (2006). Cyclical intravenous pamidronate treatment affects metaphyseal modeling in growing patients with osteogenesis imperfecta. J. Bone Miner. Res., 21:374–379.
   PubMed Web of Science ®Google Scholar
• Pizones, J., Plotkin, H., Parra-Garcia, J.I., (2005). Bone healing in children with osteogenesis imperfecta treated with bisphosphonates. J. Pediatr. Orthop., 25:332–335.
   PubMed Web of Science ®Google Scholar
• Chan, B., and Zacharin, M. (2006). Maternal and infant outcome after pamidronate treatment of polyostotic fibrous dysplasia and osteogenesis imperfecta before conception: a report of four cases. J. Clin. Endocrinol. Metab., 91:2017–2020.
   PubMed Web of Science ®Google Scholar
• Teitelbaum, S.L. (2007). Osteoclasts: what do they do and how do they do it?. Am. J. Pathol., 170:427–435.
   PubMed Web of Science ®Google Scholar
• de Vernejoul, M.C. (2008). Sclerosing bone disorders. Best Prac. Res. Clin. Rheumatol., 22:71–83.
   PubMed Web of Science ®Google Scholar
• Tanaka, S., Nakamura, K., Takahasi, N., (2005). Role of RANKL in physiological and pathological bone resorption and therapeutics targeting the RANKL-RANK signaling system. Immunol. Rev., 208:30–49.
   PubMed Web of Science ®Google Scholar
• Bone, H.G., Bolognese, M.A., Yuen, C.K., (2008). Effects of denosumab on bone mineral density and bone turnover in postmenopausal women. J. Clin. Endocrinol. Metab., 93:2149–2157.
   PubMed Web of Science ®Google Scholar
• Brown, J.P., Prince, R.L., Deal, C., (2009). Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial. J. Bone Miner. Res., 24:153–161.
   PubMed Web of Science ®Google Scholar
• Kostenuik, P.J.N.H., McCabe, J., Warmington, K., Kurahara, C., Sun, N., Chen, C., Li, L., Cattley, R.C., Van, G., Scully, S., Elliott, R., Grisanti, M., Morony, S., Tan, H.L., Asuncion, F., Li, X., Ominsky, M.S., Stolina, M., Dwyer, D., Dougall, W.C., Hawkins, N., Boyle, W.J., Simonet, W.S., and Sullivan, J.K. (2009). Denosumab, a fully human monoclonal antibody to RANKL, inhibits bone resorption and increases bone density in knock-in mice that express chimeric (human/murine) RANKL. J. Bone Miner. Res., 24:182–195.
   PubMed Web of Science ®Google Scholar
• Miller, R.E., Branstetter, D., Armstrong, A., (2007). Receptor activator of NF-kappa B ligand inhibition suppresses bone resorption and hypercalcemia but does not affect host immune responses to influenza infection. J. Immunol., 179:266–274.
   PubMed Web of Science ®Google Scholar
• Chipman, S.D., Sweet, H.O., McBride, D.J., Jr., (1993). Defective pro alpha 2(I) collagen synthesis in a recessive mutation in mice: a model of human osteogenesis imperfecta. Proc. Natl. Acad. Sci. USA, 90:1701–1705.
   PubMed Web of Science ®Google Scholar
• Camacho, N.P., Raggio, C.L., Doty, S.B., (2001). A controlled study of the effects of alendronate in a growing mouse model of osteogenesis imperfecta. Calcif. Tissue Int., 69:94–101.
   PubMed Web of Science ®Google Scholar
• Evans, K.D., Lau, S.T., Oberbauer, A.M., (2003). Alendronate affects long bone length and growth plate morphology in the oim mouse model for osteogenesis Imperfecta. Bone, 32:268–274.
   PubMed Web of Science ®Google Scholar
• McCarthy, E.A., Raggio, C.L., and Hossack, M.D., (2002). Alendronate treatment for infants with osteogenesis imperfecta: demonstration of efficacy in a mouse model. Pediatr. Res. 52:660–670.
   PubMed Web of Science ®Google Scholar
• Misof, B.M., Roschger, P., Baldini, T., (2005). Differential effects of alendronate treatment on bone from growing osteogenesis imperfecta and wild-type mouse. Bone, 36:150–158.
   PubMed Web of Science ®Google Scholar
• King, D., Jarjoura, D., McEwen, H.A., (2005). Growth hormone injections improve bone quality in a mouse model of osteogenesis imperfecta. J. Bone Miner. Res., 20:987–993.
   PubMed Web of Science ®Google Scholar
• Bonadio, J., Jepsen, K.J., Mansoura, M.K., (1993). A murine skeletal adaptation that significantly increases cortical bone mechanical properties. Implications for human skeletal fragility. J. Clin. Invest., 92:1697–1705.
   PubMed Web of Science ®Google Scholar
• Kamoun-Goldrat, A.S., and Le Merrer, M.F. (2007). Animal models of osteogenesis imperfecta and related syndromes. J. Bone Miner. Metab., 25:211–218.
   PubMed Web of Science ®Google Scholar
• Kozloff, K.M., Carden, A., Bergwitz, C., (2004). Brittle IV mouse model for osteogenesis imperfecta IV demonstrates postpubertal adaptations to improve whole bone strength. J. Bone Miner. Res., 19:614–622.
   PubMed Web of Science ®Google Scholar
• Sillence, D.O., Ritchie, H.E., Dibbayawan, T., (1993). Fragilitas ossium (fro/fro) in the mouse: a model for a recessively inherited type of osteogenesis imperfecta. Am. J. Med. Genet., 45:276–283.
   PubMed Web of Science ®Google Scholar
• Fisher, S., Jagadeeswaran, P., and Halpern, M.E. (2003). Radiographic analysis of zebrafish skeletal defects. Dev. Biol., 264:64–76.
   PubMed Web of Science ®Google Scholar
• Uveges, T.E., Kozloff, K.M., Ty, J.M., Ledgard, F., Raggio, C.L., Gronowicz, G., Goldstein, S.A., and Marini, J.C. (2009). Alendronate ttreatment of Brtl osteogenesis imprefacta mouse improves geometry and load response before fracture but decreases predicted material properties and has detrimental effects on osteoblasts and bone formation. J. Bone Miner. Res., 24(5):849–59.
   Web of Science ®Google Scholar
• Delos, D., Yang, X., Ricciardi, B.F., (2008). The effects of RANKL inhibition on fracture healing and bone strength in a mouse model of osteogenesis imperfecta. J. Orthop. Res., 26:153–164.
   PubMed Web of Science ®Google Scholar
• Turner, C.H., and Burr, D.B. (1993). Basic biomechanical measurements of bone: a tutorial. Bone, 14:595–608.
   PubMed Web of Science ®Google Scholar
• Huang, A.R.C, Fritton, J., and Camacho, N. (2005). Comparison of radiographic and micro-CT determined parameters in mouse bone specimens. 51st annual meeting of the Orthopaedic Research Society.
   Google Scholar
• Van Der Meulen, M.C., Jepsen, K.J., and Miki, B. (2001). Understanding bone strength: size isn't everything. Bone, 29:101–104.
   PubMed Web of Science ®Google Scholar
• Van Slyke, M.A., and Marks, S.C., Jr. (1987). Failure of normal osteoclasts to resorb calcified cartilage from osteosclerotic (oc/oc) mice in vitro. Bone, 8:39–44.
   PubMed Web of Science ®Google Scholar
• Faden, M.A., Krakow, D., Ezgu, F., (2009). The Erlenmeyer flask bone deformity in the skeletal dysplasias. Am. J. Med. Genet., 149A(6):1334–45
   Web of Science ®Google Scholar
• Cho, T.J., Choi, I.H., Chung, C.Y., (2005). Efficacy of oral alendronate in children with osteogenesis imperfecta. J. Pediatr. Orthop., 25:607–612.
   PubMed Web of Science ®Google Scholar
• Rauch, F., Cornibert, S., Cheung, M., (2007). Long-bone changes after pamidronate discontinuation in children and adolescents with osteogenesis imperfecta. Bone, 40:821–827.
   PubMed Web of Science ®Google Scholar
• Bonnick, S., Saag, K.G., Kiel, D.P., (2006). Comparison of weekly treatment of postmenopausal osteoporosis with alendronate versus risedronate over two years. J. Clin. Endocrinol. Metab., 91:2631–2637.
   PubMed Web of Science ®Google Scholar
• Rosen, C.J., Hochberg, M.C., and Bonnick, S.L., (2005). Treatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: a randomized double-blind study. [see comment]. J. Bone Miner. Res., 20:141–151.
   PubMed Web of Science ®Google Scholar
• Delmas, P.D., and Seeman, E. (2004). Changes in bone mineral density explain little of the reduction in vertebral or nonvertebral fracture risk with anti-resorptive therapy. [see comment]. Bone, 34:599–604.
   PubMed Web of Science ®Google Scholar
• Plotkin, L.I., Aguirre, J.I., Kousteni, S., (2005). Bisphosphonates and estrogens inhibit osteocyte apoptosis via distinct molecular mechanisms downstream of extracellular signal-regulated kinase activation. J. Biol. Chem., 280:7317–7325.
   PubMed Web of Science ®Google Scholar
• Plotkin, L.I., Weinstein, R.S., Parfitt, A.M., (1999). Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin. J. Clin. Invest., 104:1363–1374.
   PubMed Web of Science ®Google Scholar
• Samadfam, R., Xia, Q., and Goltzman, D. (2007). Co-treatment of PTH with osteoprotegerin or alendronate increases its anabolic effect on the skeleton of oophorectomized mice. J. Bone Miner. Res., 22:55–63.
   PubMed Web of Science ®Google Scholar
• Albright, J.A., and Grunt, J.A. (1971). Studies of patients with osteogenesis imperfecta. J. Bone Joint Surg. Amer., 53:1415–1425.
   PubMed Web of Science ®Google Scholar
• Flick, L.M., Weaver, J.M., Ulrich-Vinther, M., (2003). Effects of receptor activator of NFkappaB (RANK) signaling blockade on fracture healing. J. Orthop. Res., 21:676–684.
   PubMed Web of Science ®Google Scholar